Migraine Drugs Market Is Growing At A CAGR of 18.0% from 2018 to 2025: Grand View Research, Inc.

Posted on 2018-12-11 by researchinsights in Healthcare, Pharmaceuticals // 0 Comments

San Francisco, United States, 2018-Dec-11 — /EPR Network/ —The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

To request a sample copy or view summary of this report:
www.grandviewresearch.com/industry-analysis/migraine-drugs-market

Further key findings from the report suggest:

Germany leads the European market, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
The acute migraine treatment market will be supported by rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
Biohaven’s rimegepant is expected to face competition from Allergan’s ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Related Report of Pharmaceuticals:

Grand View Research has segmented the global migraine drugs market based on treatment, therapeutic class, route of administration, and country:

Migraine Drugs Treatment Outlook (Revenue, USD Million, 2017 – 2025)

Acute / Abortive Treatment
Preventive/ Prophylactic Treatment

Migraine Drugs Therapeutic Class Outlook (Revenue, USD Million, 2017 – 2025)

Triptans
Acetylcholine Inhibitors
Ergot Alkaloids
NSAIDs
Ditans
CGRP small molecule antagonists
CGRP monoclonal antibodies
Others

Migraine Drugs Route of Administration Outlook (Revenue, USD Million, 2017 – 2025)

Oral
Injectables
Others

Migraine Drugs Country Outlook (Revenue, USD Million, 2017 – 2025)

U.S.
U.K.
France
Germany
Italy
Spain
Japan

Access Press Release Of This Research Report by Grand View Research: www.grandviewresearch.com/press-release/global-migraine-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Matched content

Editor’s pick